SCHEMBL8533657

SCHEMBL8533657

C=CCc1cc(C=C2SCN(C)C2=O)cc(CC=C)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
PTGS2 P35354 2/20 0.37
ALOX5 P09917 1/20 0.37
PTGS1 P23219 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PTPN1 P18031 5/20 0.36
NAT1 P18440 3/20 0.35
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8533654 1.00 GAA (0.39) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL7796827 0.88 MEN1 (0.40) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL7796826 0.88 MEN1 (0.40) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL8957287 0.87 CYP1A2 (0.50) GAAALDH1A1MEN1KMT2APOLB
SCHEMBL8532254 0.83 CYP1A2 (0.40) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL8532250 0.83 CYP1A2 (0.40) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL8580786 0.83 KDM4E (0.35) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL8991952 0.83 KDM4E (0.35) GAAKDM4EALDH1A1MEN1KMT2A
SCHEMBL8537136 0.78 MEN1 (0.50) GAAALDH1A1MEN1KMT2APOLB
SCHEMBL8537140 0.78 MEN1 (0.50) GAAALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
US-5691367-A ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS ELI LILLY AND COMPANY (US) 1997-11-25 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed